Acadia pharmaceuticals presents clinical data from across multiple therapeutic programs at the 2025 international congress of parkinson's disease and movement disorders®

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the international congress of parkinson's disease and movement disorders® being held october 5-9, 2025, in honolulu, hawaii. the presentations highlight updates from the company's robust pipeline including preclinical efficacy, safety and mechanism of action findings on acadia's investigational drug acp-711, under deve.
ACAD Ratings Summary
ACAD Quant Ranking